Literature DB >> 9099469

Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.

M Merello1, R Pikielny, A Cammarota, R Leiguarda.   

Abstract

Twelve parkinsonian patients with severely fluctuating symptoms were given a single dose of apomorphine or Dispersible Madopar on 2 consecutive days, to confirm the latter drug's usefulness in "off" period rescue. According to our results, apomorphine proved faster in reverting "off" periods and should still be regarded as the drug of choice for this treatment modality.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099469     DOI: 10.1097/00002826-199704000-00008

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  11 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 3.  Novel Levodopa Formulations for Parkinson's Disease.

Authors:  Maria Eliza Freitas; Marta Ruiz-Lopez; Susan H Fox
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749

Review 4.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Authors:  R Katzenschlager; A Evans; A Manson; P N Patsalos; N Ratnaraj; H Watt; L Timmermann; R Van der Giessen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

Review 6.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

Review 7.  Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?

Authors:  Stuart H Isaacson; Fernando L Pagan; Mark F Lew; Rajesh Pahwa
Journal:  Clin Park Relat Disord       Date:  2022-08-12

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

9.  Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.

Authors:  Roberto Cilia; Janeth Laguna; Erica Cassani; Emanuele Cereda; Nicolò G Pozzi; Ioannis U Isaias; Manuela Contin; Michela Barichella; Gianni Pezzoli
Journal:  Neurology       Date:  2017-07-05       Impact factor: 9.910

Review 10.  Medical Management and Prevention of Motor Complications in Parkinson's Disease.

Authors:  Stephen D Aradi; Robert A Hauser
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.